ウィルソン病治療の世界市場：2024年～2031年

レポート概要

世界のウィルソン病治療市場は、2023年に5億9,825万米ドルに達し、2031年には9億1,691万米ドルに達し、予測期間2024年～2031年のCAGRは5.6%で成長すると予測されています。

ウィルソン病は、体内の銅の異常蓄積によって引き起こされる遺伝病です。治療しなければ、この病気は肝臓、目、脳、その他の臓器に蓄積された銅のために、生命を脅かす臓器障害を引き起こす可能性があります。ウィルソン病の診断は、家族歴、身体検査、眼科検査、血液検査、尿検査に基づいて行われます。肝生検や画像検査を行うこともあります。

ウィルソン病の治療は亜鉛などの薬物療法で行われます。ウィルソン病の患者さんは、臓器障害を軽減または予防するために、症状を管理するための生涯にわたる治療が必要です。ウィルソン病は急性肝不全を引き起こす可能性があり、肝移植が必要になることもあります。

市場力学：

促進要因と阻害要因

患者の意識の高まり

様々な組織や団体によるウィルソン病やその症状に関する認知度の向上は、世界中で人口が増加していることに伴い、治療市場の活性化につながると予想されます。キャンペーンや活動を通じた個人の意識の高まりは、ウィルソン病の早期診断につながる可能性があります。このような認識により、早期診断が促進され、治療オプションの需要が増加する可能性があります。

個人の間で希少疾患に対する関心が高まっています。ウィルソン病の患者数の増加に伴い、個人の間でも意識が高まっています。2023年のAmerican Liver Foundationの発表によると、ウィルソン病は30,000人に1人が罹患するとされています。したがって、上記の要因が市場の成長を促進すると予想されます。

キレート剤に伴う副作用

キレート剤に関連する副作用は、骨髄抑制や腎臓合併症など深刻です。銅キレート剤のその他の一般的な副作用には、脱力感／疲労感、腹痛、味覚喪失、胸焼け、食欲不振（食欲の欠如または喪失）、青白い皮膚などがあります。このように、副作用は市場の成長を妨げます。

市場セグメント分析

銅キレート剤治療セグメントが市場シェアを独占する見込み

キレート剤は、症状緩和を達成するための第一選択薬です。ペニシラミンとトリエンチンは、ウィルソン病の治療に使用される2つのキレート剤です。これらの薬は体内の過剰な銅濃度を減少させます。

高い効率とウィルソン病の症状を管理する能力により、これらの薬剤は他のタイプよりも需要が高まっています。製薬会社は新薬の研究開発を強化しています。製品の承認が増加することで、セグメントの成長が高まる可能性があります。

例えば、2022年5月、オルファランSAはトリエンチンの新塩（トリエンチン四塩酸塩）であるCuvriorの米国食品医薬品局（FDA）承認を取得しました。Cuvriorは、ペニシラミンに脱抑制・耐容性のある安定型ウィルソン病成人患者の治療薬として承認されています。

地域別市場分析

北米はウィルソン病治療市場シェアで重要な位置を占めると予想される

予測期間中、北米が世界のウィルソン病治療市場を独占しているが、これは主にこれらの地域における老人人口の急速な増加などの要因によるものです。さらに、確立されたヘルスケアインフラ、可処分所得の増加、研究開発活動への投資の増加が北米のシェア拡大に寄与しています。

ウィルソン病の有病率の上昇も市場の成長に寄与しています。診断と治療に関する個人の意識の高まりは、病気と利用可能な治療法について個人を教育する可能性があります。このように、上記の要因は同地域の市場成長を促進すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 患者の意識の高まり
  • 抑制要因
    • キレート剤に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIオピニオン

第6章 治療別

• 銅キレート薬
  • ペニシラミン
  • トリエンチン
  • テトラチオモリブデン酸塩
  • その他
• 亜鉛サプリメント
• その他

第7章 投与経路別

• 経口
• 非経口
• その他

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• 政府流通チャネル

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Bausch Health Companies Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Teva Pharmaceutical Industries Ltd.
• Noblepharma Co., Ltd.
• Taj Pharmaceuticals Limited.
• Lupin Limited
• Dr. Reddy's Laboratories Inc.
• Recordati S.p.A
• Nextwell Pharmaceutical Private Limited
• AstraZeneca Plc
• Pfizer Inc.（*LIST NOT EXHAUSTIVE）

第12章 付録

Report Overview

Global Wilson's Disease Treatment Market reached US$ 598.25 million in 2023 and is expected to reach US$ 916.91 million by 2031, growing at a CAGR of 5.6% during the forecast period 2024-2031.

Wilson's disease is a genetic disorder caused by abnormal copper accumulation in the body. Without treatment, the disease can cause life-threatening organ damage due to the copper built up in the liver, eyes, brain, and other organs. The diagnosis of Wilson's disease is based on family history, physical exams, eye exams, blood tests, and urine tests. Liver biopsy and imaging tests may also be used.

Treatment of Wilson's disease is done with medication such as zinc. Patients who have Wilson's disease need lifelong treatment to manage symptoms to reduce or prevent organ damage. Wilson's disease can cause acute liver failure which may lead to the need for a liver transplant.

Market Dynamics: Drivers & Restraints

Increasing awareness among patients

The increasing awareness regarding Wilson's disease by various organizations and associations and its symptoms along with the growing population all over the world is expected to fuel the treatment market. Rising awareness among individuals with the campaigns and activities could lead to earlier diagnosis of Wilson's disease. This awareness could drive individuals to early diagnosis which can increase the demand for treatment options.

There is a rising concern among individuals regarding rare diseases. With the rising number of individuals with the condition, there is growing awareness among individuals. According to a publication by the American Liver Foundation in 2023, it is stated that 1 in 30,000 individuals suffer from Wilson's disease. Thus, the above factors are expected to drive the market growth.

Side effects associated with chelators

Side effects associated with chelators are severe such as bone marrow suppression and kidney complications. Other common side effects of copper chelators include weakness/tiredness, abdominal pain, loss of taste, heartburn, anorexia (lack or loss of appetite), and pale skin among others. Thus, the side effects hamper the market growth.

Market Segment Analysis

The global Wilson's disease treatment market is segmented based on medication, route of administration, distribution channel, and region.

Copper chelating medications treatment segment is expected to dominate the market share

Chelators are the first line of treatment for achieving symptomatic relief. Penicillamine and trientine are two chelating agents used to treat Wilson's disease. These medicines deplete the excessive copper levels from the body.

With high efficiency and the ability to manage the symptoms of Wilson's disease, these agents are gaining demand over the other types. Pharmaceutical companies are raising the research and development of new medications. The increasing approvals of the products could increase the segment growth.

For instance, in May 2022, Orphalan SA received the United States Food and Drug Administration (FDA) approval for Cuvrior, a new salt of trientine (trientine tetrahydrochloride). Cuvrior is approved for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine.

Market Geographical Analysis

North America is expected to hold a significant position in the Wilson's disease treatment market share

North America dominates the global Wilson's Disease Treatment market during the forecast period and it is primarily attributed to factors such as rapid growth in the geriatric population in these regions. Moreover, the established healthcare infrastructure the rising disposable income, and higher investment in R&D activities contribute to the growth of North America's share.

The rising prevalence of Wilson's disease also contributes to the growth of the market. The rising awareness among individuals regarding the diagnosis and treatment could educate individuals about the disease and available treatments. Thus, the above factors are expected to drive the region's market growth.

Market Segmentation

By Treatment

• Copper Chelating Medications
  • Penicillamine
  • Trientine
  • Tetrathiomolybdate
  • Others
• Zinc Supplements
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Government Distribution Channel

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the market include Bausch Health Companies Inc., Teva Pharmaceutical Industries Ltd., Noblepharma Co., Ltd., Taj Pharmaceuticals Limited., Lupin Limited, Dr. Reddy's Laboratories Inc., Recordati S.p.A, Nextwell Pharmaceutical Private Limited, AstraZeneca Plc and Pfizer Inc. among others.

Why Purchase the Report?

• To visualize the global Wilson's disease treatment market segmentation based on medication, route of administration, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Wilson's disease treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global Wilson's disease treatment market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Medication
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing awareness among patients
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with chelators
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Treatment

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 6.1.2. Market Attractiveness Index, By Treatment
• 6.2. Copper Chelating Medications*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Penicillamine
  • 6.2.4. Trientine
  • 6.2.5. Tetrathiomolybdate
  • 6.2.6. Others
• 6.3. Zinc Supplements
• 6.4. Others

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Oral*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Parenteral
• 7.4. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies
• 8.5. Government Distribution Channel

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
    • 9.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 9.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.3.1. The U.S.
    • 9.2.3.2. Canada
    • 9.2.3.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
    • 9.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 9.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.4.1. Germany
    • 9.3.4.2. UK
    • 9.3.4.3. France
    • 9.3.4.4. Italy
    • 9.3.4.5. Spain
    • 9.3.4.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
    • 9.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 9.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.4.1. Brazil
    • 9.4.4.2. Argentina
    • 9.4.4.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
    • 9.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 9.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.4.1. China
    • 9.5.4.2. India
    • 9.5.4.3. Japan
    • 9.5.4.4. South Korea
    • 9.5.4.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
    • 9.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 9.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Bausch Health Companies Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Teva Pharmaceutical Industries Ltd.
• 11.3. Noblepharma Co., Ltd.
• 11.4. Taj Pharmaceuticals Limited.
• 11.5. Lupin Limited
• 11.6. Dr. Reddy's Laboratories Inc.
• 11.7. Recordati S.p.A
• 11.8. Nextwell Pharmaceutical Private Limited
• 11.9. AstraZeneca Plc
• 11.10. Pfizer Inc. (*LIST NOT EXHAUSTIVE)

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us